Lineage Cell Therapeutics Inc (LCTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $231.35M
Last updated: Nov 17, 2026 at 11:06 AM ET
Lineage Cell Therapeutics Inc (LCTX) Stock Forecast
Analysts expect Lineage Cell Therapeutics (LCTX) to earn -$0.07 per share in the fiscal year ending Dec 31, 2026, on revenue of $15.19M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$0.14.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 5 | 71.4% |
| Hold | 1 | 14.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 10.8%.
- Fiscal year ending Dec 31, 2026
- -$0.07
- EPS consensus, revenue $15.19M
- Fiscal year ending Dec 31, 2027
- -$0.14
- EPS consensus, revenue $16.83M
- Next report
- Mar 3, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.13 to $0.04 | 4 | $15.19M | $2.79M to $36.43M | 7 |
| Dec 31, 2027 | -$0.14 | -$0.16 to -$0.12 | 4 | $16.83M | N/A | 7 |
Quarterly Estimates
The EPS consensus falls from $0.00 for the quarter ending Dec 31, 2026 to -$0.03 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.00 | -$0.04 to $0.08 | 9 | $4.21M | N/A | 9 |
| Mar 31, 2027 | -$0.03 | -$0.03 to -$0.03 | 3 | $1.51M | $1.07M to $2.41M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 is where it was 90 days ago.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.07 | -$0.06 | -$0.06 | -$0.07 | -$0.07 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.14 | -$0.10 | -$0.10 | -$0.09 | -$0.09 | N/A |
| Quarter ending Mar 31, 2027 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | -$0.03 | N/A |
Frequently Asked Questions About LCTX
What is the LCTX stock forecast?
Consensus analyst estimates put Lineage Cell Therapeutics's EPS at -$0.07 for the fiscal year ending Dec 31, 2026, on revenue of $15.19M. The consensus rating from 7 analysts is Buy.
How do analysts rate LCTX stock?
Of 7 analysts covering Lineage Cell Therapeutics, 1 rates it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LCTX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.07, with estimates from -$0.13 to $0.04 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.14, with estimates from -$0.16 to -$0.12 from 4 analysts.
What revenue do analysts expect from Lineage Cell Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $15.19M, with estimates from $2.79M to $36.43M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $16.83M.
How many analysts cover LCTX?
7 analysts rate Lineage Cell Therapeutics stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
LCTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors